Rebel News reporter Avi Yemini spoke to AstraZeneca Chief Executive Officer Marc Dunoyer as he entered the World Economic Forum meeting in Davos, Switzerland.
Dunoyer’s biography on AstraZeneca’s website:
Marc became CEO of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. He had previously served as an Executive Director and AstraZeneca’s Chief Financial Officer from November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!